



2021 Updates

ICD O 3.2 and Solid Tumor Rules


Introduction

Origin of ICD-O-3.2 Codes

Relationship Between WHO and ICD-O-3.2

How ICD-O-3.2 Changes Get Implemented

ICD-O-3.2 Coming in 2021



3

ICD-O-3.2: What, When, and Where

- **What:** Incorporates all new codes, terminology, behavior updates from WHO 4th Ed Blue Book Series
- **When:** Effective for cases diagnosed **January 1, 2021**
- **Where:** <https://www.naaccr.org/icdo3/>
- **As of December 9, 2020, ICD-O-3.2 is available in Excel format only. Due to Covid-19, the editors of the pdf version are currently tasked with other responsibilities. The pdf version is still planned.**

4



2021 ICD-O-3.2 Implementation

Guidelines for ICD-O-3 Update

Summary of Tables of Changes for 2021

How to Use the Tables

Review of the Tables



Implementation Guidelines for ICD-O-3.2 Update

- Effective for cases diagnosed January 1, 2021 forward
- Use of implementation guidelines is **required** for determining reportability and accurate coding
- Tables provide information on changes to reportability, codes, and terminology
 - Use for pre-2021 diagnoses when histology not listed in the Solid Tumor Rules
- Access at NAACCR website
 - <https://www.naacccr.org/icdo3/> ←

Implementation Guidelines for ICD-O-3.2 Update

- NAACCR implemented some new codes in 2018 based on changes in WHO Blue Books, which show up as 2021 changes in ICD-O-3.2 documentation from IARC.
- The Update Tables 1-7 may **not** document all changes in histology/behavior between the NAACCR 2018 ICD-O-3 implementation and the 2021 implementation of ICD-O-3.2.
 - Always refer to the complete listing of codes in ICD-O-3.2 to verify histology and behavior codes if the Solid Tumor Rules do not provide an exact match of diagnostic terminology and codes.

7

7 Tables of Changes for 2021

Table	Description	# Items
1	Behavior code changes- non-reportable to reportable	16
2	Behavior code changes- reportable to non-reportable	9
3	Deleted codes- histology terms moved to other codes	10
4	Change in reportable terminology	13
5	New codes and terms	12
		Order
6	Tables 1-5 plus new preferred & related terms, synonyms	Numerical
7	Tables 1-5 plus new preferred & related terms, synonyms	Alphabetical

NOTE: Some of the tables may be updated from how they appear in this presentation. Always use the current official tables available on the NAACCR website at <https://www.naacccr.org/icdo3/>

8

Table 1: Behavior Change Non-Reportable to Reportable

- WHO changed behavior codes for several terms which resulted in previously non-reportable neoplasms becoming reportable for cases diagnosed 1/1/2021 forward
- **DO NOT** report cases diagnosed **prior** to 1/1/2021
 - Review Table 1 to confirm reportability of pre-2021 diagnoses

9

Table 1: Non-reportable to Reportable

ICD-O Code	Term	Change
8077/2	Squamous intraepithelial neoplasia, grade II	Change from /0
8150/3	Pancreatic endocrine tumor, NOS (C254)	Change from /1
8151/3	Insulinoma, NOS (C25.4)	Change from /0
8158/3	ACTH-producing tumor	Change from /1
8380/2	Endometrioid intraepithelial neoplasia (C54.1)	New behavior & term
8408/3	Aggressive digital papillary adenoma (C44. _)	Change from /1
8452/3	Solid pseudopapillary neoplasm of pancreas	Change from /1
8320/3	Granulosa cell tumor, adult type (C56.9)	Reportable 1/1/2021 forward
8690/3	Middle ear paraganglioma (C30.1, C75.5)	Change from /1
8691/3	Aortic body tumor (C75.5)	Change from /1
8692/3	Carotid body paraganglioma (C75.4)	Change from /1
8693/3	Extra-adrenal paraganglioma, NOS	Change from /1
8700/3	Pheochromocytoma, NOS (C74.1)	Change from /0
8963/3	Gastrointestinal autonomic nerve tumor (GIST)	Change from /1
9505/0	Multinodular and vasculating neuronal tumor (MVNT) (C71.2)	Per CBTRUS
9766/3	Lymphomatoid granulomatosis, grade 3	New behavior & term

10

Table 2: Behavior Change Reportable to Non-Reportable

- WHO changed behavior codes for several terms which resulted in previously reportable neoplasms becoming non-reportable for cases diagnosed 1/1/2021 forward
- **DO NOT** report cases diagnosed **on or after** 1/1/2021
 - **Exception:** /1 histologies occurring in a CNS or Intracranial site are reportable
- Review Table 2 to confirm reportability of pre-2021 diagnoses

11

Table 2: Reportable to Non-reportable

ICD-O Code	Term	Change
8832/1	Dermatofibrosarcoma protuberans, NOS (C44. _)	Change from /3
8833/1	Pigmented dermatofibrosarcoma protuberans (C44. _)	Change from /3
9080/1	Immature teratoma of lung, thymus, thyroid	Change from /3
9709/1	Primary cutaneous CD4-positive small/medium T cell lymphoma (C44. _)	Change from /3
9718/1	Primary subcutaneous CD30+ T cell lymphoproliferative disorder	Change from /3
9725/1	Hydroa vacciniforme-like lymphoproliferative disorder	Change from /3
9751/1	Langerhans cell histiocytosis, NOS	Change from /3
9971/1	Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD)	Change from /3
8335/1	Follicular carcinoma, encapsulated (C73.9)	Change from /3

12

Table 3: Deleted & Moved ICD-O Codes

ICD-O-3/3.1 Code/Beh	Term	3.2 code 1/1/2021	Comments
8471/3	Papillary mucinous cystadenocarcinoma (C56.9)	8470/3	DX'd prior to 1/1/2021, code to 8471/3 DX'd 1/1/2021 forward code to 8470/3
9150/3	Hemangiopericytoma, malignant	8815/3	DX'd prior to 1/1/2021 code to 9150/3 DX'd 1/1/2021 forward code to 8815/3
9360/3	Ewing sarcoma	9364/3	DX'd prior to 1/1/2021 code to 9360/3 DX'd 1/1/2021 forward code to 9364/3
9670/3	Malignant lymphoma, small B lymphocytic, NOS (see M-9823/3)	9823/3	DX'd prior to 1/1/2021 code to 9670/3 DX'd 1/1/2021 forward code to 9823/3
9728/3	Precursor B-cell lymphoblastic lymphoma (see M-9836/3)	9811/3	DX'd prior to 1/1/2021 code to 9728/3 DX'd 1/1/2021 forward code to 9811/3
9729/3	Precursor T-cell lymphoblastic lymphoma (see M-9837/3)	9837/3	DX'd prior to 1/1/2021, code to 9729/3 DX'd 1/1/2021 forward code to 9837/3
9826/3	Burkitt cell leukemia (see M-9687/3)	9687/3	DX'd prior to 1/1/2021 code to 9826/3 DX'd 1/1/2021 forward code to 9687/3
9836/3	Precursor B-cell lymphoblastic leukemia (see M-9738/3)	9811/3	DX'd prior to 1/1/2021 code to 9836/3 DX'd 1/1/2021 forward code to 9811/3
9991/3	Refractory neutropenia	9980/3	DX'd prior to 1/1/2021 code to 9991/3 DX'd 1/1/2021 forward code to 9980/3
9992/3	Refractory thrombocytopenia	9980/3	DX'd prior to 1/1/2021 code to 9992/3 DX'd 1/1/2021 forward code to 9980/3

13

Table 4: Change in Reportable Terminology

ICD-O-3.2 Code	Term
8151/3	Insulinoma, NOS
8152/3	Glucagonoma, NOS
8153/3	Gastrinoma, NOS
8155/3	VIPoma, NOS
8156/3	Somatostatinoma, NOS
8580/3	Thymoma, NOS (C37.9)
8581/3	Type A Thymoma including atypical variant (C37.9)
8582/3	Type AB thymoma (C37.9)
8583/3	Type B1 thymoma (C37.9)
8584/3	Type B2 thymoma (C37.9)
8585/3	Type B3 thymoma (C37.9)
8680/3	Paraganglioma, NOS
8700/3	Pheochromocytoma, NOS

Matrix Principle applies:
If diagnosed specifically as benign or borderline, change behavior accordingly

14

Table 5: New Terms and ICD-O Codes

ICD-O-3.2 Code	Term
8273/3	Pituitary blastoma
9715/3	Anaplastic large cell lymphoma ALK-negative Breast implant-associated anaplastic large cell lymphoma
9749/3	Erdheim-Chester Disease
9766/3	Lymphomatoid granulomatosis, grade 3
9819/3	B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like
9877/3	Acute myeloid leukemia with mutated NPM1
9878/3	Acute myeloid leukemia with biallelic mutation of CEBPA
9879/3	Acute myeloid leukemia with mutated RUNX1
9912/3	Acute myeloid leukemia with BCR-ABL1
9968/3	Myeloid/lymphoid neoplasm with PCM1-JAK2
9993/3	Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia

15

Excerpt from Table 7 (Alphabetical order)

Status	ICD-O-3.2 Morphology Code	Term(s)	Reportable Y/N	Comments
RT	8140/3	Acinar adenocarcinoma of prostate (C61.9)	Y	
Syn	8744/3	Acral lentiginous melanoma, malignant (C44. _)	Y	
PT	8744/3	Acral melanoma (C44. _)	Y	
BC	8158/3	ACTH-producing tumor	Y	Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021
PT	9840/3	Acute erythroid leukemia	Y	
CC	9687/3	Acute leukemia, Burkitt type [obs]	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
CC	9687/3	Acute lymphoblastic leukemia, mature B-cell type	Y	Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3
NC/T	9912/3	Acute myeloid leukemia with BCR-ABL1	Y	Reportable for cases diagnosed 1/1/2021 forward

Status Abbreviations in Tables 6 and 7 (Combined Tables)

Status	Definition
BC	Behavior code change (Change in reportability)
CC	Code change: codes deleted, and histology terms moved to other codes
NC/T	New ICD-O code and term
PT	Preferred term
RT	Related term
Syn	Synonym

PT: Squamous intraepithelial neoplasia, high grade
Syn of PT: Squamous intraepithelial neoplasia, grade III
RT: Anal intraepithelial neoplasia, grade III (C21.1)
Syn of RT: AIN III (C21.1)

All coded to 8077/2

17

Topography Codes in Update Tables

ICD-O-3

- Topography (C code) listed next to morphology term means that is the most common primary site

Update Tables

- Topography (C code) listed next to morphology term may be site-specific and may not apply to other sites
- Site- and histology-specific combinations will not be added to the “impossible combination” edit
 - Interfield edit 25 may apply and could require review

18

Annotated Histology List <https://www.naaccr.org/icdo3/>

8550	1	FALSE	Tumor, acinic cell [obs]
8550	3	TRUE	Acinar cell carcinoma [EXCLUDES C61.9, USE 8140/3 FOR PROSTATE]
8550	3	FALSE	Acinar adenocarcinoma [USE FOR LUNG < 2018 DX. FOR LUNG 2018+ USE 8551/3. EXCLUDES C61.9, USE 8140/3 FOR PROSTATE]
8550	3	FALSE	Acinar carcinoma [EXCLUDES C61.9, USE 8140/3 FOR PROSTATE]
8550	3	FALSE	Acinar cell carcinoma [EXCLUDES C61.9, USE 8140/3 FOR PROSTATE]
8550	3	FALSE	Acinic cell adenocarcinoma [EXCLUDES C61.9, USE 8140/3 FOR PROSTATE]
8550	3	FALSE	Adenocarcinoma, acinar [EXCLUDES C61.9, USE 8140/3 FOR PROSTATE]
8580	0	TRUE	Thymoma, benign (C37.9)
8580	1	TRUE	Thymoma, NOS (C37.9) [PRE-2021 ONLY. FOR 2021+ USE CODE 8580/3.]
8580	3	TRUE	Thymoma, NOS (C37.9) [2021+]
8580	3	FALSE	Intrapulmonary thymoma (C34._) [2021+]
8580	3	FALSE	Metaplastic thymoma (C37.9) [2021+]



2021 Reportability and Casefinding



Impact on Casefinding and Reportability

Major changes apply to reportability for 2021

- **16** previously non-reportable neoplasms become reportable (Table 1)
- **9** reportable pre-2021 neoplasms become non-reportable (Table 2)
- **10** histology terms have been moved to other ICD-O codes (Table 3)
- **13** histologies have a change in reportable terminology (Table 4)
- **12** new terms/ICD-O codes (Table 5)

Cancer Registry reportability rules based on behavior still apply

- /2 and /3 behavior reportable for all sites
- /0 and /1 behavior reportable for primary intracranial and CNS
- Certain exceptions....refer to the standard setters to whom you report (NCDB, NPCR, SEER, State/regional registry)

21

Tables with Reportability Implications

Table	Description	# Items
1	Behavior code changes- non-reportable to reportable	16
2	Behavior code changes- reportable to non-reportable	9
3	Deleted codes- histology terms moved to other codes	10
4	Change in reportable terminology	13
5	New codes and terms	12
		Order
6	Tables 1-5 plus new preferred & related terms, synonyms	Numerical
7	Tables 1-5 plus new preferred & related terms, synonyms	Alphabetical

22

Casefinding

- **FY2021 ICD-10-CM Casefinding List** [[PDF Format](#) (PDF, 321 KB)] [[Excel Format](#) (XLSX, 83 KB)]

Effective dates: 10/1/2020 - 9/30/2021

- <https://seer.cancer.gov/tools/casefinding/>
- Per SEER Casefinding List (PDF)
*Please refer to your standard setter(s) for specific reporting requirements **before** using the Casefinding List.*

23

Reportability and ICD-O-3.2 Morphology


Practical Approach to Reportability

- For 2021 diagnoses, use ICD-O-3.2
- For pre-2021 **solid tumor** diagnoses, use update table 6 or 7, or the annotated histology list in conjunction with ICD-O3.2 to determine:
 - Reportability (careful with CNS and intracranial sites)
 - Morphology
- For heme/lymphoid diagnoses (pre- or post-2021), use the heme manual/database

25

Practical Approach to Reportability

Reportability requirements of standard setter(s) to whom you are reporting



26

Practical Approach to Assigning Histology

Solid Tumors

1. Solid tumor “H” rules
 - Tables may not have all terminology listed
 - Other sites rules don’t have histology tables
2. ICD-O-3.2
 - If pre-2021 dx, consult update table 6 or 7 (or use annotated histology list) to confirm correct histology/behavior
3. Ask a SEER Registrar

27

Practical Approach to Assigning Histology

Hematopoietic and Lymphoid Neoplasms

1. Hematopoietic Database and Manual
2. Ask a SEER Registrar

28

Practice Case 1

9/12/2021 Descending colon, bx: Adenocarcinoma in a polyp

Step 1: Open the Colon Solid Tumor Rules to the Single Tumor Histology Rules

- Rule H2: Code the histology and ignore the polyp when a carcinoma originates in a polyp
- Rule H7: Code the histology when a single histology is present

Step 2: Go to Table 1: Specific Histologies, NOS, and Subtypes/Variants

Step 3: Assign the histology:

29

Practice Case 2

8/24/2021 BSO: High grade serous carcinoma

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor Invasive Only Histology Rules

- **Rule H11** Code the histology when only **one histologic type** is identified
 - No histology tables (other than some combined codes) in the Other Sites rules

Step 2: Go to ICD-O-3.2

- Row 859 is an exact match

Step 3: Assign the histology:

30

Practice Case 3

8/24/2021 Endometrium, bx: Endometrioid carcinoma with squamous differentiation

Step 1: Open the Other Sites Solid Tumor Rules to the *Single Tumor Invasive Only* Histology Rules

- **Rule H11** Code the histology when only **one histologic type** is identified

Step 2: Go to ICD-O-3.2

- Row 1080 is an exact match

Step 3: Assign the histology:

31

Practice Case 4

6/15/2021 Thyroid FNA: Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor In Situ Only Histology Rules

- **Rule H2** Code the histology when only **one histologic type** is identified

Step 2: Search the term in ICD-O-3.2

- Row 685 is an exact match (8349/1)

Reportable? _____

(Optional) Confirm the term is not reportable in the update tables (6 or 7)

32

Practice Case 5

2/5/2021 RUL lung biopsy: Oat cell carcinoma

Step 1: Open the Lung STRs to the Single Tumor Histology Rules

- Rule H4 Code the histology when only **one histology** is present

Step 2: Go to Table 3 : Specific Histologies, NOS, and Subtypes/Variants

- Oat cell carcinoma is not listed

Step 3: Go to ICD-O-3.2

- Row 80 is an exact match (Oat cell carcinoma)

Step 4: Assign the histology:

33

Practice Case 6

3/13/2021 Skin, Lt shoulder: Aggressive digital papillary adenoma

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor Invasive Only Histology Rules

- **Rule H11** Code the histology when only **one histologic type** is identified
 - No histology tables (other than some combined codes) in the Other Sites rules

Step 2: Search the term in ICD-O-3.2

Step 3: Assign the histology:

34

Practice Case 7

3/13/2020 Skin, Lt shoulder: Aggressive digital papillary adenoma

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor Invasive Only Histology Rules

- **Rule H11** Code the histology when only **one histologic type** is identified
 - No histology tables (other than some combined codes) in the Other Sites rules

Step 2: Search the term in ICD-O-3.2

Step 3: Consult update table 6 or 7

Practice Case 8

4/12/2021 Rt ovary: Papillary pseudomucinous cystadenocarcinoma

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor Invasive Only Histology Rules

- Rule H11 Code the histology when only **one histologic type** is identified

Step 2: Search the term in ICD-O-3.2

Step 3: Assign the histology:

Practice Case 9

4/12/2018 Rt ovary: Papillary pseudomucinous cystadenocarcinoma

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor Histology Rules

- Rule H11 Code the histology when only **one histologic type** is identified

Step 2: Search the term in ICD-O-3.2

Step 3: Search the term in Update Tables 6 or 7 (pre-2021 case)

Step 4: Assign the histology:

37

Practice Case 10

5/11/2021 Thymus: Thymoma, organoid

Step 1: Open the Other Sites Solid Tumor Rules to the Single Tumor Invasive Only Histology Rules

- Rule H11 Code the histology when only **one histologic type** is identified
 - No histology tables (other than some combined codes) in the Other Sites rules

Step 2: Search the term in ICD-O-3.2

Step 3: Assign the histology:

Note: 2021 STORE states only report thymomas when they are multifocal or have LN or other mets. SEER and NPCR require thymomas w/ malignant behavior in ICD-O-3.2.

38

Practice Case 11

7/17/2021 Bone marrow: Post-transplant lymphoproliferative disorder

Step 1: Search the term in the Hematopoietic Database

Reportable ___

This neoplasm is not reportable.

Name

Polymorphic post-transplant lymphoproliferative disorder

ICD-O-3 Morphology

Effective 2021 and later

9971/1: Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD)

Not Reportable

This neoplasm is not reportable

ICD-O-3.2 confirms the assignment of /1 to this code: row 2915

39

Practice Case 12

11/3/2021 Pituitary gland: Langerhans cell histiocytosis

Step 1: Search the term in the Hematopoietic Database

This neoplasm is not reportable.

Name

LCH, NOS

ICD-O-3 Morphology

Effective 2021 and later

9751/1: Langerhans cell histiocytosis

Not Reportable

This neoplasm is not reportable

Reportable ___

For CNS and intracranial sites, /0 and /1 **ARE** reportable! This is stated in the Abstractor notes section of the heme database.

Step 1: Assign the histology per the heme database _____

ICD-O-3.2 confirms the assignment of /1 to this code: row 2629

40

The logo features the acronym "NAACCR" in a white, bold, serif font with a slight shadow effect. It is centered within a solid green circle. This green circle is set against a larger, light gray circular background that is partially obscured by the corners of the page.

NAACCR

THANK YOU
